Towards universal access: scaling up
priority HIV/AIDS interventions in the
health sector
Progress report 2009
Slide set – six summary data slides
and all 40 figures from the report
Increase in antiretroviral therapy in low- and middle-income countries,
adults and children [combined], December 2007–December 2008
Geographical region
Sub-Saharan Africa
Number of people
receiving ARV
therapy
Number of
people receiving
ARV therapy
December 2008
December 2007
Increase
in one
year
2 925 000
2 100 000
39%
Latin America and the Caribbean
445 000
390 000
14%
East, South and South-East Asia
565 000
420 000
35%
Europe and Central Asia
85 000
54 000
39%
North Africa and the Middle East
10 000
7 000
43%
4 030 000
2 970 000
36%
[3.7–4.4 million]
[2.7–3.3 million]
Total
2|
Towards universal access: progress report 2009 | 24 July 2016
Antiretroviral therapy coverage in low- and middle-income countries,
adults and children [combined], December 2008
Geographical region
Sub-Saharan Africa
Estimated number
of people receiving
ARV therapy
Estimated
number of people
needing ARV
therapy
Antiretroviral
therapy
coverage
2 925 000
6 700 000
44%
Latin America and the Caribbean
445 000
820 000
54%
East, South and South-East Asia
565 000
1 500 000
37%
Europe and Central Asia
85 000
370 000
23%
North Africa and the Middle East
10 000
68 000
14%
4 030 000
9 500 000
42%
[3.7–4.4 million]
[8.6–10 million]
[40–47%]
Total
3|
Towards universal access: progress report 2009 | 24 July 2016
Antiretroviral therapy coverage in low- and middle-income countries,
adults (≥15 years), December 2008
Geographical region
Sub-Saharan Africa
Reported number
of adults (≥15
years) receiving
ARV therapy
Estimated
number of adults
needing ARV
therapy
Antiretroviral
therapy
coverage
2 700 000
6 100 000
44%
Latin America and the Caribbean
429 000
800 000
54%
East, South and South-East Asia
537 000
1 500 000
36%
80 000
370 000
22%
9 400
62 000
15%
8 800 000
43%
[8.1–9.5 million]
[39–46%]
Europe and Central Asia
North Africa and the Middle East
Total
4|
3 755 000
Towards universal access: progress report 2009 | 24 July 2016
Antiretroviral therapy coverage in low- and middle-income countries,
children (0–14 years), December 2008
Geographical region
Sub-Saharan Africa
Reported number
of children (0–14
years) receiving
ARV therapy
Estimated
number of
children needing
ARV therapy
Antiretroviral
therapy
coverage
224 900
640 000
35%
Latin America and the Caribbean
16 100
21 000
76%
East, South and South-East Asia
30 000
58 000
52%
4 200
4 900
85%
400
6 700
6%
730 000
38%
[580 000–880 000]
[31–47%]
Europe and Central Asia
North Africa and the Middle East
Total
5|
275 700
Towards universal access: progress report 2009 | 24 July 2016
Prevention of mother-to-child transmission coverage in low- and middleincome countries, December 2008
Geographical region
Estimated
number of
pregnant women
living with HIV
needing ARVs for
PMTCT
Prevention of
mother-tochild
transmission
coverage
576 800
1 280 000
45%
Latin America and the Caribbean
17 100
32 000
54%
East, South and South-East Asia
21 700
85 000
25%
Europe and Central Asia
12 600
13 400
94%
<200
13 400
1%
1 400 000
45%
[1.1–1.7 million]
[37–57%]
Sub-Saharan Africa
Reported number
of pregnant
women living with
HIV receiving
ARVs for PMTCT
North Africa and the Middle East
Total
6|
628 400
Towards universal access: progress report 2009 | 24 July 2016
Number of people receiving antiretroviral therapy in low- and
middle-income countries, by region, 2002–2008
4.5
North Africa and the Middle East
4.0
Europe and Central Asia
3.5
East, South and South-East Asia
Latin America and the Caribbean
3.0
Millions
Sub-Saharan Africa
2.5
2.0
1.5
1.0
0.5
0.0
End 2002
7|
End 2003
End 2004
End 2005
Towards universal access: progress report 2009 | 24 July 2016
End 2006
End 2007
End 2008
Fig. 2.1. Transaction volumes of rapid HIV tests, 2004–2008
8|
Towards universal access: progress report 2009 | 24 July 2016
Fig. 2.2. Reported number of health facilities providing HIV testing and
counselling services in low- and middle-income countries with comparable
data, by region, 2007 and 2008
9|
Towards universal access: progress report 2009 | 24 July 2016
Fig. 2.3. Percentage of women with HIV testing and counselling and
percentage of women with secondary or higher education, district
comprehensive assessment districts in Burkina Faso, Haiti and Zambia,
2008
10 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 2.4. Percentage of women and men receiving an HIV test and test
results in the 12 months preceding the survey in countries with repeat
population surveys, 2003–2008
11 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 2.5. Percentage of women and men (≥15 years) who had ever received
an HIV test and test results, South Africa, 2002, 2005 and 2008
12 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 3.1. Situation analysis of harm reduction interventions in the Middle
East and North Africa at baseline, 2008
13 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 3.2. Blood donation per 1000 population, 2007
14 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.1. Number of people receiving antiretroviral therapy in low- and
middle-income countries, by region, 2002–2008
15 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.2. Measuring attrition from antiretroviral therapy programmes
16 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.3. Retention on antiretroviral therapy at 12 months after initiation of
treatment in 61 low- and middle-income countries by region, 2008
17 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.4. 12-month retention of people receiving antiretroviral therapy in
selected treatment sites, Papua New Guinea, 2008
18 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.5. Trends in retention on antiretroviral therapy in low- and middleincome countries by region, 2008
19 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.6. Trends over time in the median CD4 count at baseline count of
36 715 adults starting antiretroviral therapy between 2001 and 2006
20 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.7. Antiretroviral therapy coverage and all-cause mortality in South
Africa, 2003–2006
21 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.8. Countries implementing at least one element of the WHO Global
Strategy for the Prevention and Assessment of HIV Drug Resistance and
locations of HIV drug resistance testing laboratories, February 2009
22 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.9. Main first-line antiretroviral regimens used among 2.4 million
adults in 36 low- and middle-income countries, December 2008
23 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.10. Main second-line antiretroviral regimens used among adults
(n=51 135) in 36 low- and middle-income countries, December 2008
24 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.11. First-line regimens used among children (n=177 064) in 36 lowand middle-income countries, December 2008
25 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.12. Second-line regimens used among children (n=5997) in 35 lowand middle-income countries, December 2008
26 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.13. Median annual cost (in US dollars) of first-line antiretroviral drug
regimens in low-income countries by year, 2004–2008
27 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.14. Median annual cost (in US dollars) of first-line antiretroviral drug
regimens in lower-middle-income countries by year, 2004–2008
28 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.15. Median price (in US dollars) of first-line antiretroviral drug
regimens in upper-middle-income countries by year, 2004–2008
29 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.16. Estimated HIV prevalence (%) among people newly infected with
TB, 2007
30 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 4.17. Rates of HIV testing among people with TB in countries in subSaharan Africa, 2004–2007
31 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.1. Number of low- and middle-income countries with national scaleup plans including population-based targets for preventing mother-to-child
transmission and for HIV care and treatment for children, by region, 2008
32 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.2. Percentage of women and men aged 15–49 years with
comprehensive knowledgea of HIV in countries with recent populationbased surveys (2007–2008)
33 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.3. Reported percentage condom use at last sexual intercourse among
women 15–49 years old who had sex in the past year by five-year age
groups in selected population-based surveys, 2005–2007
34 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.4. Unmet need for family planning among married women 15–49
years old (%) in countries with a generalized epidemic, 2006–2008
35 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.5. Percentage of pregnant women who received an HIV test in lowand middle-income countries by region, 2004–2008a
36 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.6. Percentage of pregnant women who received an HIV test in Malawi,
2004–2008
37 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.7. Percentage of pregnant women with HIV receiving antiretrovirals
for preventing mother-to-child transmission of HIV in low- and middleincome countries by region, 2004–2008
38 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.8. Percentage of pregnant women living with HIV who received
antiretrovirals to prevent mother-to-child transmission of HIV in Côte
d’Ivoire, 2005–2008
39 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.9. Percentage of pregnant women living with HIV receiving
antiretrovirals to prevent the mother-to-child transmission of HIV in 20
countries with the highest HIV disease burden among pregnant women (in
descending order), 2008
40 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.10. Coverage of antiretrovirals to prevent the mother-to-child
transmission of HIV, 2008
41 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.11. Percentage distribution of various antiretroviral regimens
provided to pregnant women in low- and medium-income countries in 2007
and 2008, based on available data
42 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.12. Contribution of the 20 countries with the largest numbers of
women needing antiretrovirals for preventing the mother-to-child
transmission of HIV to the global gap to reach 80% of those in need, 2008
43 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.13. Coverage of antiretroviral prophylaxis among infants born to
mothers living with HIV in low- and middle-income countries by region,
2008
44 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.14. Percentage of pregnant women living with HIV and infants born to
them who received antiretrovirals for preventing mother-to-child
transmission, 2004–2008
45 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.15. Average age of infants at their first HIV DNA test in Namibia in
weeks, 2006–2008
46 |
Towards universal access: progress report 2009 | 24 July 2016
Fig. 5.16. Percentage of children receiving antiretroviral therapy in low- and
middle-income countries, 2005–2008
47 |
Towards universal access: progress report 2009 | 24 July 2016